Safety Study of GRNOPC1 in Spinal Cord Injury

General Information

Summary The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Description Not Provided
Clinical trials phase Phase 1
Start date (estimated) 2010-10-01
End date (estimated) 2013-07-31
Clinical feature
Label Spinal Cord Injury
Description Traumatic damage of the spinal cord.

Administrative Information

NCT number NCT01217008
ICTRP weblink
Other study identifiers
Name CP35A007
Source weblink
Regulatory body approval
Name Food and Drug Administration (FDA)
United States
Public contact
United States
Sponsors Asterias Biotherapeutics, Inc

Cell Line

Stem cell lines obtained from


Recruitment Status Completed
Estimated number of participants 5